TCGA-CR-7367-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- UV_RESPONSE_DN+0.400
- ANGIOGENESIS+0.370
- HEDGEHOG_SIGNALING+0.340
- KRAS_SIGNALING_UP+0.320
- MYC_TARGETS_V2+0.220
- NOTCH_SIGNALING+0.220
- TGF_BETA_SIGNALING+0.220
- APICAL_SURFACE+0.170
- ESTROGEN_RESPONSE_EARLY+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- OXIDATIVE_PHOSPHORYLATION-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.420
- DNA_REPAIR-0.390
- INTERFERON_GAMMA_RESPONSE-0.360
- E2F_TARGETS-0.290
- FATTY_ACID_METABOLISM-0.290
- P53_PATHWAY-0.290
- ADIPOGENESIS-0.270
- UV_RESPONSE_UP-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | f825534d-5882-4efe-a32e-af56741854f6 | — | — | 0.788 |
| 2 | 90407c8f-6193-45c7-9f29-0783aeeab94d | — | — | 0.783 |
| 3 | e040e6c8-34e5-44fb-a6f3-c247009fccfc | — | — | 0.757 |
| 4 | MBCProject_0217_T1_RNA | — | C | 0.751 |
| 5 | TCGA-BB-A5HU-01A-11R-A28V-07 | — | — | 0.749 |
| 6 | TCGA-OR-A5J2-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.747 |
| 7 | TCGA-CN-6989-01A-11R-1915-07 | — | — | 0.747 |
| 8 | TCGA-A8-A08Z-01A-21R-A00Z-07 | — | A | 0.738 |
| 9 | SRR25043621 | — | — | 0.737 |
| 10 | 7900174d-af00-444f-a5b2-226a45f7e76a | — | — | 0.734 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| COMPLEMENT | 0.090 | Inavolisib | — uncovered |